Navigation Links
Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
Date:1/24/2013

health systems," said Ashoka President Diana Wells . "We have found that in tackling health from a systems level, most of our social entrepreneurs are finding ways to 1) deliver unlikely allies to solve the healthcare practitioner shortage  or 2) are innovating new delivery systems which can reach low income populations in both urban and rural areas.  We are excited to partner with Boehringer Ingelheim once again to tap the transformative power of social entrepreneurship and to solve one of the most critical issues that is confronting society today."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Social responsibility is a core element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of its global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic values of all of Boehringer Ingelheim's endeavors.

For more information please visit www.boehringer-ingelheim.com

About Ashoka Changemakers

Ashoka Changemakers is a community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and funding ideas to solve the world's most pressing social
'/>"/>

SOURCE Ashoka Changemakers
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Omnicell, Inc . (NASDAQ: OMCL ... solutions and analytics software for healthcare facilities, today announced ... medication automation products for clinical use in China. ... Chinese hospitals to access advances in operational improvements similar ...
... N.J., Nov. 28, 2011  Johnson & Johnson (NYSE: JNJ ... Health Care Conference on Tuesday, Nov. 29 th at The ... Ethicon will present in a session scheduled at 8:00 a.m. (Eastern ... and other interested parties by accessing the Johnson & Johnson website ...
Cached Medicine Technology:Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 2Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 3Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 4Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 5
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... a colored ribbon representing a disease. A pink ribbon is ... does one think of with lung cancer?, Although white has ... the disease, black may be the only one they think ... patients, primarily smokers between the ages of 51 to 79 ... felt by these patients, the emotional toll it can have ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... eye’s retina is well on its way to offering ... as retinitis pigmentosa and age-related degeneration of the eye ... implant works for eye diseases in which healthy retinal ... eye’s photoreceptors.// These receptors convert images into electric impulses. Researchers ...
... Andhra Pradesh are to have a common e-platform which ... with the inauguration of www.aponline.gov.in, the state government's latest ... departments under one umbrella. The portal is being developed ... joint venture agreement.While TCS is enjoying 89% of the ...
... a common problem for heavy drinkers and the scientist have ... support the potentialities of a night out. ,Researchers at ... Clinic in Minnesota say the effect of alcohol on blood ... of healthy young adults, that blood vessels do not strengthen ...
... as the world's worst pandemic if the 40 million people ... drugs. The illness has killed 25 million people since the ... with HIV, which destroys the immune system. ,Without ... the death toll beyond the 40 million killed// by the ...
... babies suffer from asphyxia, which can lead to brain injury, ... per cent of babies who suffer from a moderate lack ... currently no effective treatments to reduce the risk of asphyxia ... lowering a baby's temperature may have beneficial effects. ,UK ...
... alpha gene are the cause of premature menopause which is ... of the total population. ,The University of Auckland team ... genetic test, which would allow women// with a family history ... They analysed DNA from women who had experienced POF, which ...
Cached Medicine News:
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
Medicine Products: